Iocarmic acid

Iocarmic acid is a specialized organoiodine compound that has garnered attention in the medical community due to its pivotal role as a contrast medium in diagnostic radiographic procedures.

Chemical and Physical Properties[edit]

Being an iodinated molecule, iocarmic acid's primary asset lies in its ability to absorb X-rays with greater efficiency than the surrounding human tissues. This property stems from the high iodine content within the molecule, making it particularly effective at enhancing the contrast in radiographic images^[1].

Clinical Utility[edit]

Iocarmic acid is employed in a diverse range of imaging studies to improve the visualization of structures and vessels, including:

By emphasizing the disparity between the organ or vessel of interest and its adjacent structures, iocarmic acid significantly augments the diagnostic accuracy of these procedures^[2].

Pharmacokinetics[edit]

Upon intravascular administration, iocarmic acid disseminates into the extracellular fluid compartment. Its removal from the system is predominantly orchestrated by renal excretion. As a result, the rate of its clearance closely mirrors renal function, underscoring the need for dosage adjustments in patients with renal insufficiencies^[3].

Safety Profile and Potential Adverse Reactions[edit]

While iocarmic acid generally manifests a favorable safety profile for a majority of patients, vigilant monitoring for potential adverse effects remains paramount. Common reactions include:

Warmth or flushing sensation at the site of injection
Transient nausea or dizziness

However, rare but severe reactions might include:

Anaphylactic shock
Hypotensive episodes
Respiratory compromise

Immediate clinical intervention is warranted in the face of such adverse reactions^[4].

Conclusion[edit]

The advent of iocarmic acid has greatly advanced the field of radiology by offering a reliable and effective contrast medium for various diagnostic studies. Its ability to sharply delineate anatomical structures has proven invaluable for both clinicians and researchers alike.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

References[edit]

Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. Radiology, 180(1), 13-21.
Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. Rofo, 191(1), 24-30.
Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine, 352(3), 239-246.
Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. JAMA, 299(23), 2773-2783.

↑ Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. Radiology, 180(1), 13-21.
↑ Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. Rofo, 191(1), 24-30.
↑ Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine, 352(3), 239-246.
↑ Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. JAMA, 299(23), 2773-2783.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. Radiology, 180(1), 13-21.

[2] Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. Rofo, 191(1), 24-30.

[3] Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine, 352(3), 239-246.

[4] Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. JAMA, 299(23), 2773-2783.

[1]

[2]

[3]

[4]